News | February 08, 2022
Granules India Q3FY22 PAT at Rs 100.88 cr.
Granules India has reported consolidated financial results for the period ended December 31, 2021
Granules India has reported consolidated financial results for the period ended December 31, 2021
Key takeaways of recent quarter & conference call highlights
Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
The stability is led by healthy demand in the domestic and emerging markets
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
Subscribe To Our Newsletter & Stay Updated
